News 06.04.2021 Zurich-Schlieren, Switzerland, April 06, 2021. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced that the first patient has been dosed in a Phase 2a clinical trial of ensovibep, a DARPin® therapeutic candidate designed...
News 25.03.2021 Zurich-Schlieren, Switzerland, March 25, 2021. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced the nomination of Dominik Höchli, M.D., to the Company’s Board of Directors proposed for election at the 2021 Annual General...
News 22.03.2021 Zurich-Schlieren, Switzerland, March 22, 2021. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, today announced that it plans to conduct a registered public offering of its ordinary shares, in the form of American Depositary Shares...
News 18.03.2021 Schlieren (Zurich), Switzerland, March 18, 2021 – Kuros Biosciences closed the year with outstanding results for 2020, accelerating sales by 58% and initiating the Phase II study for Fibrin PTH, confirming its successful transition into a fully-fledged orthobiologics company with scientific, clinical, and commercial excellence in bone regeneration. Kuros raised gross proceeds...
News 15.03.2021 Zurich-Schlieren, Switzerland, March 15, 2021. Molecular Partners AG (SIX: MOLN), a clinical-stage biotech company that is developing a new class of custom-built protein drugs known as DARPin® therapeutics, and its collaborator Novartis, today announced today announced that ensovibep (formerly MP0420) is expected to be included in a global phase 3...